There is an old saying in medicine: “above all do no harm.” This term often comes into play when our patients ask us about nutritional products for diabetes and other diseases, as well as when someone tells us about the greatest new exercise program to “cure” diabetes. This week we …
Read More »Monthly Archives: July 2016
Canagliflozin as a Monotherapy in Type 2 Diabetes
Is the SGLT-2 inhibitor best used along with metformin, or is canagliflozin as a monotherapy a good choice?
Read More »Effect of Lipid Lowering Drugs on Type 2 Diabetes
ETC-1002 may offer new therapeutic option that does not decrease glycemic control.
Read More »Should We Exercise at a Particular Time of the Day, or at Our Convenience?
Is there a best time to work out, based on circadian rhythms?
Read More »The Use of Technology in Medical Practice
How do consumers and HCPs feel about new technologies and their impact on our health system?
Read More »Diabetes, Kidney Problems and Cardiovascular Risk in Minority Patients
Prevalence of early CKD higher among Hispanics and African Americans.
Read More »Can Aloe Vera Play a Role in Managing Type 2 Diabetes?
Studies suggest aloe vera has antidiabetic properties, but is the research sound?
Read More »Question #844
Which of the following is the correct diagnostic cut-point for diabetes? 1) A1C greater than or equal to 7% 2) Fasting plasma glucose (FPG) greater than or equal to 130 mg/dL 3) 2-hour plasma glucose greater than or equal to 200 mg/dL during an oral glucose tolerance test 4) Random plasma glucose greater than or equal to 300mg/dL in a patient with classics symptoms of hyperglycemia or hyperglycemic crisis Did you get it right? Follow the link to find out!
Read More »To Bike or Not to Bike?
Do you enjoy and ride a bike for exercise? Follow the link to respond!
Read More »July 26, 2016
There are various hormones, neurotransmitters, nucleotides, and fatty acids in the pancreas that affect insulin production and secretion. Sorting all these factors out, and how we might possibly affect glucose control by mimicking some of these compounds, has opened up new avenues of treatment. GLP-1 agonists are just one example. This week in our …
Read More »